Bodies used in immunohistochemistry experi-ments. (DOC)Table S3 Antibodies used in western blots experiments.(DOC)Author ContributionsConceived and designed the experiments: FFF DAM. Performed the experiments: FFF DAM. Analyzed the data: FFF PRPC JDTAN SSME MT VLC RRG DAM. Contributed reagents/materials/analysis tools: FFF PRPC JDTAN SSME MT VLC RRG DAM. 25033180 Wrote the paper: FFF DAM.
It is well recognized that the 4-aminopyridine- (4-AP-) sensitive transient outward potassium current Ito is expressed in cardiomyocytes from mouse [1,2], rat [3], rabbit [4], ferret [5], cat [6], canine [7], and human [8], but not in cardiomyocytes from guinea pig [9] and pig hearts [10,11]. Ito is heterogeneously expressed in transmural ventricular wall of the hearts in human and dogs, determines the morphologies of cardiac action potentials, and generates the prominent phase 1 repolarization and “spike and dome” profile of ventricular epicardial and midmyocardial myocytes in these species [7,12]. In human and canine hearts, Ito is principally encoded by Kv4.3 (KCND3) gene [13,14]. Recent studies have demonstrated that Brugada syndrome-associated Ito gain-of-function mutations in KCND3-encoded Kv4.3 is believed to mediate an A196 chemical information alteration of transmural voltage gradient (epicardium . endocardium), and result in a net outward shift in current and heterogeneous loss of the action potential dome, ST segment elevation on electrocardiogram (ECG), and the development of potentially fatal polymorphic ventricular tachycardia or ventricular fibrillation via phase II reentry [15]. Our previous study [16] has demonstrated the natural flavone acacetin, in addition to blocking human atrial ultra-rapidlydelayed rectifier potassium current (IKur) and acetylcholineactivated potassium current (IK.ACh), effectively inhibits human atrial Ito. This compound increased the atrial effective refractoryperiod and prevented the occurrence of atrial fibrillation in anesthetized dogs without prolonging the QT interval [16]. Our recent study has shown that the natural flavone acacetin is an open channel blocker of hKv1.5 channels with use- and 25033180 Wrote the paper: FFF DAM.
It is well recognized that the 4-aminopyridine- (4-AP-) sensitive transient outward potassium current Ito is expressed in cardiomyocytes from mouse [1,2], rat [3], rabbit [4], ferret [5], cat [6], canine [7], and human [8], but not in cardiomyocytes from guinea pig [9] and pig hearts [10,11]. Ito is heterogeneously expressed in transmural ventricular wall of the hearts in human and dogs, determines the morphologies of cardiac action potentials, and generates the prominent phase 1 repolarization and “spike and dome” profile of ventricular epicardial and midmyocardial myocytes in these species [7,12]. In human and canine hearts, Ito is principally encoded by Kv4.3 (KCND3) gene [13,14]. Recent studies have demonstrated that Brugada syndrome-associated Ito gain-of-function mutations in KCND3-encoded Kv4.3 is believed to mediate an alteration of transmural voltage gradient (epicardium . endocardium), and result in a net outward shift in current and heterogeneous loss of the action potential dome, ST segment elevation on electrocardiogram (ECG), and the development of potentially fatal polymorphic ventricular tachycardia or ventricular fibrillation via phase II reentry [15]. Our previous study [16] has demonstrated the natural flavone acacetin, in addition to blocking human atrial ultra-rapidlydelayed rectifier potassium current (IKur) and acetylcholineactivated potassium current (IK.ACh), effectively inhibits human atrial Ito. This compound increased the atrial effective refractoryperiod and prevented the occurrence of atrial fibrillation in anesthetized dogs without prolonging the QT interval [16]. Our recent study has shown that the natural flavone acacetin is an open channel blocker of hKv1.5 channels with use- and 1081537 frequencydependent blocking properties by binding to the S6 domain of the channels [17]. The present study was designed to investigate the properties and molecular determinants of acacetin for inhibiting hKv4.3 channels with whole-cell patch voltage-clamp and mutagenesis approaches.Materials and Methods Cell line culture and gene transfectionThe HEK 293 cell line [18] stably expressing the human Kv4.3 (KCND3) gene kindly provided by Dr. Klaus Steinmeyer (SanofiAventis Deutschland GmbH) was maintained in Dulbecco’s modified eagle’s medium (DMEM, Invitrogen, Hong Kong) supplemented with 10 fetal bovine serum and 400 mg/mL G418 (Sigma ldrich). Cells used for electrophysiology recording were seeded on a glass cover slip. Polymerase chain reaction-based site-directed mutagenesis was used to produce mutations of the pCDNA3.1/hKv4.3 plasmid. Primers used to generate the channel mutants were synthesized by the Genome Research Center, the University of Hong Kong (Hong Kong), and the mutants were generated using a QuikChange kit (Stratagene, La Jolla, CA), and confirmed byAcacetin Blocks hKv4.3 ChannelsDNA sequencing. The mutant was transiently expressed with 4 mg of hKv4.3 mutant cDNA plasmid using 10 ml of Lipofectamine 2000 to determine the mutant hKv4.3 currents.Drugs and solutionsAcacetin synthesized in the laboratory as described previously in the US pat.